<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi>, a potent DNA methyltransferase inhibitor, which was originally under development by Pharmachemie, is being developed by SuperGen </plain></SENT>
<SENT sid="1" pm="."><plain>Pharmachemie had been studying <z:chebi fb="0" ids="50131">decitabine</z:chebi> in phase II clinical trials for several <z:hpo ids='HP_0001909'>leukemia</z:hpo> indications in Europe and the US </plain></SENT>
<SENT sid="2" pm="."><plain>Preliminary results indicated that the compound was active in the treatment of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, relapsed <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and postallogeneic progenitor cell transplant relapse </plain></SENT>
<SENT sid="3" pm="."><plain>The compound is in phase II clinical trials with phase III trials scheduled to begin shortly </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> has been used to treat <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> in a total of 125 patients, with an overall response rate of 49% </plain></SENT>
<SENT sid="5" pm="."><plain>In a study using <z:chebi fb="0" ids="50131">decitabine</z:chebi> to treat <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in 81 patients, a response rate of 62% among patients in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of the disease was achieved </plain></SENT>
<SENT sid="6" pm="."><plain>In a phase I/II trial designed to establish safety and efficacy in the treatment of sickle cell <z:hpo ids='HP_0001903'>anemias</z:hpo> treatment with <z:chebi fb="0" ids="50131">decitabine</z:chebi> generated a response in 100% of the patients tested: a total of eight patients were enrolled, each experienced elevated levels of fetal <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Side effects were minimal and the drug was well tolerated </plain></SENT>
<SENT sid="8" pm="."><plain>Plans for additional clinical studies of <z:chebi fb="0" ids="50131">decitabine</z:chebi> as a treatment for sickle cell <z:hpo ids='HP_0001903'>anemia</z:hpo> are underway </plain></SENT>
<SENT sid="9" pm="."><plain>A phase II trial using a low dose of <z:chebi fb="0" ids="50131">decitabine</z:chebi> in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> has been completed </plain></SENT>
<SENT sid="10" pm="."><plain>Of 66 patients entered, 62 were evaluable </plain></SENT>
<SENT sid="11" pm="."><plain>The response rate was 48%, with a median response duration of 40 weeks </plain></SENT>
<SENT sid="12" pm="."><plain>The mean survival from the start of therapy was 13 months </plain></SENT>
<SENT sid="13" pm="."><plain>In a study with 37 <z:mp ids='MP_0005481'>CML</z:mp> patients, a 25% overall response rate was seen in those patients in the <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> of the disease, and a 52% response rate was observed in the accelerated phase patients </plain></SENT>
<SENT sid="14" pm="."><plain>The most significant side effect was prolonged <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>The drug suppresses cellular growth in seven human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines, possibly by reactivation of certain growth suppressor genes </plain></SENT>
</text></document>